Table 2.
Histopathological characteristics of the non-mass enhancement lesions included in our investigation.
| HISTOPATHOLOGY | n | % |
|---|---|---|
| Malignant | 39/66 | 59 |
| Ductal carcinoma in situ | 4 | 10 |
| Invasive Ductal Carcinoma | 24 | 62 |
| Invasive Lobular Carcinoma | 9 | 23 |
| IDC+DCIS | 1 | 2.5 |
| IDC+LCIS | 1 | 2.5 |
| Benign | 27/66 | 41 |
| FA/FAH | 5 | 19 |
| Adenosis, Sclerosing Adenosis, Focal Fibrosis, Apocrine metaplasia, Breast parenchyma, Fibrocystic changes | 12 | 44 |
| Papilloma | 1 | 4 |
| High-Risk (CCC with atypia, papilloma with atypia) | 2 | 7 |
| Other (chronic abscess, gynecomastia, fat necrosis, scar tissue) | 7 | 26 |
1
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; DCIS = ductal carcinoma in situ; FA = fibroadenoma; FAH = fibroadenomatoid hyperplasia; CCC = columnar cell changes.